免疫治疗在晚期或复发性宫颈癌治疗中的研究进展  

Research Progress of Immunotherapy in the Treatment of Advanced or Recurrent Cervical Cancer

作　　者：马嘉欣 张姝凤 孙晓革[2] 

机构地区：[1]内蒙古医科大学第一临床医学院,内蒙古 呼和浩特 [2]内蒙古医科大学附属医院放疗科,内蒙古 呼和浩特

出　　处：《临床医学进展》2024年第12期1550-1558,共9页Advances in Clinical Medicine

摘　　要：宫颈癌是妇科最常见的恶性肿瘤之一,以铂类为基础的同步放化疗是局部晚期宫颈癌的标准治疗,而晚期、转移性或复发性宫颈癌的治疗以全身治疗为主。近些年,随着免疫治疗的发展,免疫联合治疗(联合化疗、放疗、靶向等)成为研究热点,为晚期宫颈癌的治疗提供了新的方向,本文就与宫颈癌治疗相关的免疫检查点抑制剂的作用机制以及免疫联合传统治疗方式在晚期或复发性宫颈癌治疗中的研究进展进行综述,希望可以为晚期或复发性宫颈癌患者的治疗提供有价值的参考。Cervical cancer is one of the most common malignant tumors in gynecology, and platinum-based simultaneous radiotherapy is the standard treatment for locally advanced cervical cancer, while systemic therapy is the mainstay of treatment for advanced, metastatic or recurrent cervical cancer. In recent years, with the development of immunotherapy, combined immunotherapy (combined chemotherapy, radiotherapy, targeting, etc.) has become a research hotspot, which provides a new direction for the treatment of advanced cervical cancer. This article provides a review of the mechanism of immune checkpoint inhibitors related to the treatment of cervical cancer as well as the progress of immune-combination therapy with traditional therapeutic modalities in the treatment of advanced or recurrent cervical cancer in the hope of providing useful information for the treatment of patients with advanced or recurrent cervical cancer.

关 键 词：宫颈癌 免疫联合治疗 放疗 化疗 靶向治疗 疗效 

分 类 号：R73[医药卫生—肿瘤]